

# TRANSLIPO-TRIPLE

## Composition

Each g of **TRANSLIPO-TRIPLE** contains:

Beclomethasone dipropionate	0.025% w/w
Clotrimazole	1% w/w
Gentamicin sulphate	0.100% w/w

## Pharmacology

**TRANSLIPO-TRIPLE** contains clotrimazole, which is an imidazole antifungal, beclomethasone, which is a synthetic halogenated corticosteroid and gentamicin that is an aminoglycoside antibiotic.

Following topical application of **TRANSLIPO-TRIPLE**, beclomethasone produces anti-inflammatory and vasoconstrictor effects. Beclomethasone has been shown to have a wide range of effects on multiple cell types and mediators involved in inflammation.

Clotrimazole in **TRANSLIPO-TRIPLE** interferes with ergosterol synthesis and alters the permeability of the cell membrane of the sensitive fungi. It is fungistatic at concentrations achieved clinically.

Gentamicin has a bactericidal action against many Gram-negative aerobes and against some strains of Staphylococci. Gentamicin is taken up into sensitive bacterial cells wherein they bind to the 30S subunits of the bacterial ribosome, inhibiting protein synthesis and generating errors in the transcription of genetic code.

The antimicrobial spectrum of **TRANSLIPO-TRIPLE** includes *Blastomyces dermatidis*, *Candida* species, *Coccidioides immitis*, *Epidermophyton*, *Histoplasma capsulatum*, *Malassezia furfur*, *Microsporum*, *Paracoccidioides* and *Trichophyton*. Many strains of Gram-negative bacteria including species of *Brucella*, *Campylobacter*, *Citrobacter*, *Escherichia*, *Enterobacter*, *Klebsiella*, *Proteus*, *Pseudomonas*, *Serratia* and *Yersinia* are sensitive to **TRANSLIPO-TRIPLE**. The Gram-positive spectrum of **TRANSLIPO-TRIPLE** includes *Staphylococcus aureus*, *Listeria monocytogenes* and *Staph. epidermidis*.

**TRANSLIPO-TRIPLE** is readily absorbed from the site of local application. It has minimum systemic absorption on application to the intact skin.

## Indications

**TRANSLIPO-TRIPLE** is indicated for,

- Contact dermatitis
- Atopic dermatitis

- Eczematous dermatitis
- Napkin rash
- Dermatophytosis
- Intertrigo
- Onychomycosis

### **Contraindications**

**TRANSLIPO-TRIPLE** is contraindicated in patients with known hypersensitivity to any ingredient of the formulation.

### **Precautions**

**TRANSLIPO-TRIPLE** is to be used with caution in patients with impaired renal or hepatic function.

During discontinuation of **TRANSLIPO-TRIPLE** therapy some patients may experience symptoms of withdrawal.

**TRANSLIPO-TRIPLE** might be absorbed into the circulation. Excessive use may suppress HPA function. Therefore, it should not be combined with oral steroids.

### **Pregnancy & Lactation**

**TRANSLIPO-TRIPLE** is not to be used in pregnant and breast-feeding women.

### **Drug Interactions**

No significant drug interactions have been reported with topical use of **TRANSLIPO-TRIPLE**

### **Adverse Reactions**

**TRANSLIPO-TRIPLE** rarely causes systemic side effects. Local reactions include irritation and a burning sensation, contact dermatitis can occur rarely. On long-term local use one may experience spread or worsening of untreated infections, reversible thinning of the skin, irreversible striae atrophicae and telangiectasia, contact dermatitis and mild depigmentation.

### **Dosage & Administration**

**TRANSLIPO-TRIPLE** should be applied two or three times a day .

### **Presentation**

**TRANSLIPO-TRIPLE** is available in a tube of 10 g.